Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
MallInckrodt Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
MallInckrodt Plc, Medical Devices Deals, 2011 to YTD 2017 11
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company for up to USD410 Million 15
Biovectra to Acquire Manufacturing Facility from Sepracor Canada 17
Questcor Pharma Acquires Rights To Synacthen And Synacthen Depot 18
Mallinckrodt Completes Acquisition Of Rights To Roxicodone From Xanodyne Pharma 20
Venture Financing 21
InfaCare Pharma Raises USD3.5 Million in Venture Financing 21
Infacare Pharma Raises USD5.5 Million in Venture Financing 22
Infacare Pharma Raises USD1.3 Million in Venture Financing 23
Infacare Pharma Raises US$3.6 Million In First Tranche Of Series C Financing 24
CNS Therapeutics Secures An Additional US$0.05 Million In Venture Financing 25
Partnerships 26
Questcor Pharma Enters Into Licensing Agreement With European Company To Develop Novel Melanocortin Peptides 26
Mesoblast Enters into Agreement with Mallinckrodt Pharma 27
Valeo Pharma Enters into Distribution Agreement with Questcor Pharma for Synacthen Depot 28
INO Therapeutics Enters into Agreement with Lee’s Pharma for Inomax 29
Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 30
Fuji Pharma Enters into Distribution Agreement with Mallinckrodt 31
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 32
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 33
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 35
BioVectra Enters Into Co-Marketing Agreement With Quanta BioSciences 36
Hi-Tech Pharmacal Enters Into Co-Marketing Agreement With Mallinckrodt For TussiCaps 37
Licensing Agreements 38
West Pharma Enters into Licensing Agreement with Mallinckrodt 38
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 39
Equity Offering 40
Cadence Pharma Completes Underwritten Public Offering Of Common Stock For US$81.75 Million 40
Cadence Pharma to Raise USD75 Million in Public Offering of Shares 42
Debt Offering 43
Mallinckrodt to Raise USD750 Million in Private Placement of Notes Due 2023 43
Mallinckrodt to Raise up to USD1.2 Billion in Private Placement of Notes 44
Asset Transactions 45
Intas Pharma May Acquire Generic Drug Unit from Mallinckrodt for USD1.5 Billion 45
Piramal Enterprises Acquires Intrathecal Therapy Business from Mallinckrodt for 203 Million 46
Acquisition 47
Mallinckrodt Acquires Ocera Therapeutics for up to USD117 Million 47
Mallinckrodt Acquires InfaCare Pharma 49
Mallinckrodt Acquires Stratatech 50
Mallinckrodt Pharma Acquires Therakos from Gores Group 51
Mallinckrodt Acquires Ikaria for up to USD2.3 Billion 53
Mallinckrodt Acquires Questcor Pharma for USD5.6 Billion 55
Mallinckrodt Completes Acquisition Of Cadence Pharma For US$1.4 Billion In Tender Offer 57
Questcor Pharma Completes Acquisition Of BioVectra, Contract Manufacturing Company, For US$101 Million 59
Mallinckrodt Completes Acquisition Of CNS Therapeutics For US$100 Million 60
MallInckrodt Plc – Key Competitors 62
MallInckrodt Plc – Key Employees 63
MallInckrodt Plc – Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Recent Developments 68
Strategy And Business Planning 68
Oct 16, 2017: Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces $100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students 68
May 15, 2017: Mallinckrodt Opens New Global Centre for Medical Device R&D 69
Aug 18, 2016: Mallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment 70
Financial Announcements 71
Nov 07, 2017: Mallinckrodt Reports Earnings Results for Third Quarter of Fiscal 2017 71
Aug 08, 2017: Mallinckrodt Reports Earnings Results for Second Quarter of Fiscal 2017 73
May 08, 2017: Mallinckrodt Reports Earnings Results for First Quarter of Fiscal 2017 75
Feb 07, 2017: Mallinckrodt Reports Transition Period Results and Announces 2017 Guidance 77
Nov 29, 2016: Mallinckrodt Reports Fiscal 2016 Fourth Quarter and Full-Year Results 79
May 03, 2016: Mallinckrodt Reports Fiscal 2016 Second Quarter Results 81
Feb 02, 2016: Mallinckrodt Reports Fiscal 2016 First Quarter Results 83
Corporate Communications 85
Sep 20, 2017: Mallinckrodt Announces Election Of David Norton To Its Board Of Directors 85
May 19, 2017: Mallinckrodt Donates £100,000 to Ashford and St. Peter’s Hospitals NHS Foundation Trust to Support Neonatal Care 86
Jan 04, 2017: Karen Sheehy to Succeed Raymond Furey as Chief Compliance Officer of Mallinckrodt 87
Jun 16, 2016: Mallinckrodt Donates One Million Drug Deactivation Pouches To Support U.S. Fight Against Prescription Drug Abuse 88
May 23, 2016: Mallinckrodt Donates 250,000 Drug Deactivation Systems to ACT Missouri to Support Fight Against Prescription Drug Abuse 89
Legal and Regulatory 90
Sep 22, 2017: Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United States 90
Aug 04, 2017: Mallinckrodt Statement On Lawsuit Filed By Multnomah County, Oregon, Related To Opioid Products 91
Aug 02, 2017: Mallinckrodt Statement on U.S. DOJ Subpoena Related to Opioid Products 92
Other Significant Developments 93
Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters 93
Aug 30, 2017: Mallinckrodt Statement on Missouri Attorney General Investigation 95
Jul 27, 2017: Mallinckrodt Will Respond to Sen. McCaskill’s Request for Information on Opioid Anti-Diversion and Suspicious Order Monitoring Activities 96
Jun 21, 2017: Mallinckrodt and Massachusetts Health & Hospital Association Announce Joint Initiative for Developing Pain Stewardship Programs Within Hospitals 97
Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims 98
Apr 03, 2017: Mallinckrodt Statement on DEA and USAOs Agreement in Principle 100
Jan 18, 2017: Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC Investigation 101
May 18, 2016: Mallinckrodt to Change Fiscal Year 102
Appendix 103
Methodology 103
About GlobalData 103
Contact Us 103
Disclaimer 103
MallInckrodt Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
MallInckrodt Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
MallInckrodt Plc, Deals By Therapy Area, 2011 to YTD 2017 10
MallInckrodt Plc, Medical Devices Deals, 2011 to YTD 2017 11
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company for up to USD410 Million 15
Biovectra to Acquire Manufacturing Facility from Sepracor Canada 17
Questcor Pharma Acquires Rights To Synacthen And Synacthen Depot 18
Mallinckrodt Completes Acquisition Of Rights To Roxicodone From Xanodyne Pharma 20
InfaCare Pharma Raises USD3.5 Million in Venture Financing 21
Infacare Pharma Raises USD5.5 Million in Venture Financing 22
Infacare Pharma Raises USD1.3 Million in Venture Financing 23
Infacare Pharma Raises US$3.6 Million In First Tranche Of Series C Financing 24
CNS Therapeutics Secures An Additional US$0.05 Million In Venture Financing 25
Questcor Pharma Enters Into Licensing Agreement With European Company To Develop Novel Melanocortin Peptides 26
Mesoblast Enters into Agreement with Mallinckrodt Pharma 27
Valeo Pharma Enters into Distribution Agreement with Questcor Pharma for Synacthen Depot 28
INO Therapeutics Enters into Agreement with Lee's Pharma for Inomax 29
Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 30
Fuji Pharma Enters into Distribution Agreement with Mallinckrodt 31
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 32
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 33
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 35
BioVectra Enters Into Co-Marketing Agreement With Quanta BioSciences 36
Hi-Tech Pharmacal Enters Into Co-Marketing Agreement With Mallinckrodt For TussiCaps 37
West Pharma Enters into Licensing Agreement with Mallinckrodt 38
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 39
Cadence Pharma Completes Underwritten Public Offering Of Common Stock For US$81.75 Million 40
Cadence Pharma to Raise USD75 Million in Public Offering of Shares 42
Mallinckrodt to Raise USD750 Million in Private Placement of Notes Due 2023 43
Mallinckrodt to Raise up to USD1.2 Billion in Private Placement of Notes 44
Intas Pharma May Acquire Generic Drug Unit from Mallinckrodt for USD1.5 Billion 45
Piramal Enterprises Acquires Intrathecal Therapy Business from Mallinckrodt for 203 Million 46
Mallinckrodt Acquires Ocera Therapeutics for up to USD117 Million 47
Mallinckrodt Acquires InfaCare Pharma 49
Mallinckrodt Acquires Stratatech 50
Mallinckrodt Pharma Acquires Therakos from Gores Group 51
Mallinckrodt Acquires Ikaria for up to USD2.3 Billion 53
Mallinckrodt Acquires Questcor Pharma for USD5.6 Billion 55
Mallinckrodt Completes Acquisition Of Cadence Pharma For US$1.4 Billion In Tender Offer 57
Questcor Pharma Completes Acquisition Of BioVectra, Contract Manufacturing Company, For US$101 Million 59
Mallinckrodt Completes Acquisition Of CNS Therapeutics For US$100 Million 60
MallInckrodt Plc, Key Competitors 62
MallInckrodt Plc, Key Employees 63
MallInckrodt Plc, Other Locations 64
MallInckrodt Plc, Subsidiaries 64
